- Stocks
- Healthcare
- NYSE: EBS

Price (delayed)

$98.80

Market cap

$5.27B

P/E Ratio

17.06

Dividend/share

N/A

EPS

$5.79

Enterprise value

$5.52B

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: https://emergentbiosolutions.com/

The net income has soared by 83% from the previous quarter

EBS's EPS has soared by 82% since the previous quarter

Emergent BioSolutions's debt has increased by 8% YoY

What are the main financial stats of EBS

Market
Valuations
Earnings

Shares outstanding

53.3M

Market cap

$5.27B

Enterprise value

$5.52B

Price to earnings (P/E)

17.06

Price to book (P/B)

3.62

Price to sales (P/S)

3.35

EV/EBIT

12.59

EV/EBITDA

9.98

EV/Sales

3.55

Revenue

$1.56B

EBIT

$438.5M

EBITDA

$553M

Free cash flow

$395M

Per share
Balance sheet
Liquidity

EPS

$5.79

Free cash flow per share

$7.5

Book value per share

$27.3

Revenue per share

$29.51

TBVPS

$37.07

Total assets

$2.88B

Total liabilities

$1.44B

Debt

$874.8M

Equity

$1.45B

Working capital

$811.4M

Debt to equity

0.6

Current ratio

3.11

Quick ratio

2.22

Net debt/EBITDA

0.46

Margins
Efficiency
Dividend

EBITDA margin

35.6%

Gross margin

66.3%

Net margin

19.6%

Operating margin

27.9%

Return on assets

11.9%

Return on equity

24.5%

Return on invested capital

24.7%

Return on capital employed

17.5%

Return on sales

28.2%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Emergent BioSolutions stock price performed over time

Intraday

5.68%

1 week

-19.35%

1 month

-7.77%

1 year

60.81%

YTD

10.27%

QTD

10.27%

How have Emergent BioSolutions's revenue and profit performed over time

Revenue

$1.56B

Gross profit

$1.03B

Operating income

$433.8M

Net income

$305.1M

Gross margin

66.3%

Net margin

19.6%

The company's operating margin has surged by 171% YoY and by 47% QoQ

The net income has soared by 83% from the previous quarter

EBS's operating income has soared by 71% from the previous quarter

Emergent BioSolutions's net margin has surged by 57% QoQ

What is Emergent BioSolutions's growth rate over time

What is Emergent BioSolutions stock price valuation

P/E

17.06

P/B

3.62

P/S

3.35

EV/EBIT

12.59

EV/EBITDA

9.98

EV/Sales

3.55

EBS's EPS has soared by 82% since the previous quarter

The P/E is 74% lower than the 5-year quarterly average of 66.9 and 41% lower than the last 4 quarters average of 28.9

The price to book (P/B) is 34% higher than the 5-year quarterly average of 2.7 and 3.4% higher than the last 4 quarters average of 3.5

EBS's equity is up by 33% year-on-year and by 16% since the previous quarter

The company's revenue rose by 41% YoY and by 17% QoQ

The P/S is 8% above the 5-year quarterly average of 3.1

How efficient is Emergent BioSolutions business performance

EBS's ROS has soared by 169% year-on-year and by 46% since the previous quarter

The company's return on assets has surged by 72% QoQ

EBS's return on equity has surged by 70% since the previous quarter

EBS's ROIC has soared by 69% QoQ

What is EBS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EBS.

How did Emergent BioSolutions financials performed over time

The total assets is 101% more than the total liabilities

The total assets has grown by 24% YoY and by 10% from the previous quarter

The company's total liabilities rose by 16% YoY and by 5% QoQ

Emergent BioSolutions's debt is 40% lower than its equity

EBS's equity is up by 33% year-on-year and by 16% since the previous quarter

The debt to equity has decreased by 20% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.